CompletedNCT00212797
Two doses of Org 34517 compared with placebo for psychotic depression
About this title
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
Read the official source — NCT00212797This study evaluated the safety and effectiveness of Org 34517 for people with depression.
Medication studyAges 18–70
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Org 34517 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJuly 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 273
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00212797
- Official title
Show the full official title
Prospective, Double-Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features).
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Org 34517 for people with depression.
Who is behind this study?
The study sponsor is Merck Sharp & Dohme LLC.
Did this study involve medication?
Yes. The study involved medication, including Org 34517 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A randomized controlled clinical trial for assessing the effectiveness of pharmacogenetic information obtained with NEUROFARMAGEN in the treatment of patients with mental disorders
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode